Join our daily newsletter At The Bell to receive exclusive market insights
EVE Health Group (ASX:EVE) is aiming to enter global markets estimated to exceed US$30 billion after successfully completing research and development work on several reformulated drug candidates.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Utilising proprietary drug delivery and solubilisation technologies, the new reformulated drugs are expected to target sexual health and cardiovascular therapies.
EVE’s COO, Ben Rohr, said the company’s approach focuses on reformulating well-known pharmaceutical compounds that have established safety profiles, while developing novel delivery methods and intellectual property protection.
Initial validation of EVE’s delivery technologies has been demonstrated through the company’s lead product programs, Dyspro, a cannabinoid-based pastille targeting dysmenorrhoea, and Libbo, an oral dissolving film formulation targeting erectile dysfunction.
The company has now expanded its pipeline to include additional reformulated drug candidates addressing significant therapeutic markets.
“The completion of these programs marks another significant step in expanding EVE’s reformulation pipeline,” Mr Rohr explained today.
He continued: “Our strategy is focused on identifying high-value pharmaceutical compounds approaching patent expiry and developing improved delivery systems that enhance patient usability and outcomes.
“The addition of multiple men’s sexual health formulations, alongside the successful apixaban program and patent lodgement, further validates the versatility and commercial applicability of our technology platform.
“These programs materially expand the company’s commercial opportunities as we progress toward licensing and partnership discussions.
“These programs strengthen our position as a reformulation and delivery innovation partner for the pharmaceutical industry, and we look forward to providing further updates as we advance through the commercialisation pathway.”
The new programs are part of EVE’s broader strategy of reformulating approved pharmaceutical compounds to deliver improved bioavailability, faster onset of action, and enhanced patient usability.
The company’s research and development strategy is focused on reformulating established pharmaceutical compounds that suffer from limitations such as poor solubility, slow onset of action, or suboptimal administration formats.
By targeting drugs approaching or entering patent expiry, the company says it is looking to develop differentiated formulations that can be commercialised through licensing or supply partnerships with established pharmaceutical distribution networks.
Following completion of formulation development, EVE Health Group intends to advance these programs through further development activities, including formulation optimisation, intellectual property protection and preparation for regulatory pathway assessment in relevant jurisdictions.
EVE is up +5% to 2.1c. Mkt cap $5.697M.
Join the discussion: See what HotCopper users are saying about EVE Health Group Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
